NASDAQ:CVAC

CureVac (CVAC) Stock Forecast, Price & News

$9.36

+0.25 (+2.74%)

(As of 06/2/2023 ET)

Compare

Today's Range: $9.14
▼
$9.42
50-Day Range: $6.43
▼
$10.46
52-Week Range: $5.63
▼
$18.58

Volume: 305,197 shs
Average Volume: 651,199 shs
Market Capitalization: $2.10 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.00

CureVac MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 124.4% Upside
$21.00 Price Target
Short Interest: Bearish
4.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.63
Upright™ Environmental Score
News Sentiment: 0.17
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.04) to ($1.10) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

559th out of 983 stocks

Pharmaceutical Preparations Industry

276th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
CureVac has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.00, CureVac has a forecasted upside of 124.4% from its current price of $9.36.
Amount of Analyst Coverage
CureVac has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.63% of the float of CureVac has been sold short.
Short Interest Ratio / Days to Cover
CureVac has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in CureVac has recently increased by 19.39%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
CureVac does not currently pay a dividend.
Dividend Growth
CureVac does not have a long track record of dividend growth.

4.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
CureVac has received a 79.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "mRNA vaccines" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for CureVac is -1.63.

2.3

News and Social Media Coverage

News Sentiment
CureVac has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for CureVac this week, compared to 2 articles on an average week.
Search Interest
Only 3 people have searched for CVAC on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
MarketBeat Follows
2 people have added CureVac to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CureVac insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.15% of the stock of CureVac is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for CureVac are expected to decrease in the coming year, from ($1.04) to ($1.10) per share.
Price to Book Value per Share Ratio
CureVac has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CureVac (NASDAQ:CVAC) Stock

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Receive CVAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter.

CVAC Stock News Headlines

June 2, 2023 | americanbankingnews.com

CureVac (NASDAQ:CVAC) Shares Up 3.7%

June 1, 2023 | finance.yahoo.com

CureVac First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag

June 3, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

June 1, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: MustGrow Biologics (OtherMGROF), CureVac (CVAC) and Xenon (XENE)

May 30, 2023 | finance.yahoo.com

CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update

May 24, 2023 | finance.yahoo.com

CureVac N.V.'s (NASDAQ:CVAC) market cap surged US$362m last week, private equity firms who have a lot riding on the company were rewarded

May 24, 2023 | 247wallst.com

Peter Kolchinsky-led RA Capital's New Positions Feature CureVac, Mineralys, Pilant, Enliven Therapeu

May 22, 2023 | americanbankingnews.com

CureVac (CVAC) to Release Earnings on Tuesday

June 3, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

May 22, 2023 | americanbankingnews.com

CureVac (CVAC) to Release Quarterly Earnings on Tuesday

May 19, 2023 | finance.yahoo.com

CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech

May 8, 2023 | finance.yahoo.com

CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

May 2, 2023 | finance.yahoo.com

CureVac N.V. (NASDAQ:CVAC) Q4 2022 Earnings Call Transcript

May 1, 2023 | finance.yahoo.com

Analyst Forecasts Just Became More Bearish On CureVac N.V. (NASDAQ:CVAC)

April 30, 2023 | americanbankingnews.com

FY2023 EPS Estimates for CureVac Reduced by Jefferies Financial Group (NASDAQ:CVAC)

April 28, 2023 | americanbankingnews.com

CureVac (NASDAQ:CVAC) Price Target Cut to $24.00

April 27, 2023 | americanbankingnews.com

Jefferies Financial Group Weighs in on CureVac's Q1 2023 Earnings (NASDAQ:CVAC)

April 25, 2023 | seekingalpha.com

CureVac: Potential Of mRNA Tech Beyond Covid-19 Vaccine Development

April 25, 2023 | seekingalpha.com

CureVac N.V. 2022 Q4 - Results - Earnings Call Presentation

April 18, 2023 | finance.yahoo.com

CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023

April 17, 2023 | finance.yahoo.com

CureVac N.V.'s (NASDAQ:CVAC) Shares May Have Run Too Fast Too Soon

April 8, 2023 | americanbankingnews.com

CureVac (NASDAQ:CVAC) Trading 4.8% Higher

March 30, 2023 | americanbankingnews.com

CureVac (NASDAQ:CVAC) Shares Down 2.2%

March 23, 2023 | finance.yahoo.com

As CureVac N.V.'s market cap (NASDAQ:CVAC) drops to US$1.4b, insiders might be questioning their decision to buy earlier this year

March 17, 2023 | barrons.com

CureVac N.V.

March 17, 2023 | finance.yahoo.com

CureVac N.V. (CVAC)

February 12, 2023 | markets.businessinsider.com

EQS-News: CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares

See More Headlines

CVAC Price History

30 days | 90 days | 365 days | Advanced Chart

CVAC Company Calendar

Last Earnings: 11/29/2020
Today: 6/03/2023
Next Earnings (Estimated): 7/25/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CVAC
CUSIP: N/A
CIK: 1809122
Web: www.curevac.com
Phone: 49-70-71988-30
Fax: 49-7071-9883
Employees: 1,049
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $21.00
High Stock Price Forecast: $24.00
Low Stock Price Forecast: $18.00
Forecasted Upside/Downside: +124.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 7.61
Quick Ratio: 3.58

Sales & Book Value

Annual Sales: $72.33 million
Price / Sales: 28.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.42 per share
Price / Book: 2.74

Miscellaneous

Outstanding Shares: 223,840,000
Free Float: 219,029,000
Market Cap: $2.10 billion
Optionable: Not Optionable
Beta: 2.87

Key Executives

Dr. Franz-Werner Haas L.L.M. (Age 53)
LL.M., LLD, Ph.D., CEO, Member of Management Board & MD
Comp: $575.16k

Mr. Pierre Kemula B.Sc. (Age 48)
MD, CFO & Member of Management Board
Comp: $606.97k

Dr. Ulrike Gnad-Vogt M.D. (Age 51)
Ph.D., Interim Chief Devel. Officer, Sr. VP & Area Head of Oncology and Member of Exec. Board
Comp: $232.53k

Dr. Igor Splawski M.Sc. (Age 54)
Ph.D., Chief Scientific Officer & Member of Management Board
Comp: $430.33k

Dr. Antony Blanc Ph.D. (Age 53)
MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
Comp: $370.81k

Mr. Malte Greune Ph.D. (Age 58)
COO, Member of Management Board & MD
Comp: $354.23k

Dr. Sarah Fakih
VP Corp. Communications & Investor Relations

Mr. Marco Rau L.L.M.
Ph.D., Gen. Counsel

Mr. Thorsten Schuller
Head of Corp. Communications

Slavica Stevanovic-Heck
Head of HR

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CVAC Stock - Frequently Asked Questions

Should I buy or sell CureVac stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CVAC shares.
View CVAC analyst ratings or view top-rated stocks.
What is CureVac's stock price forecast for 2023?: 3 analysts have issued 12-month target prices for CureVac's shares. Their CVAC share price forecasts range from $18.00 to $24.00. On average, they expect the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 124.4% from the stock's current price.
View analysts price targets for CVAC or view top-rated stocks among Wall Street analysts.
How have CVAC shares performed in 2023?: CureVac's stock was trading at $6.03 at the beginning of the year. Since then, CVAC stock has increased by 55.2% and is now trading at $9.36.
View the best growth stocks for 2023 here.
Are investors shorting CureVac?: CureVac saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,310,000 shares, an increase of 19.4% from the April 30th total of 3,610,000 shares. Based on an average daily trading volume, of 561,300 shares, the short-interest ratio is currently 7.7 days. Approximately 4.6% of the shares of the company are short sold.
View CureVac's Short Interest.
When is CureVac's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our CVAC earnings forecast.
How were CureVac's earnings last quarter?: CureVac (NASDAQ:CVAC) issued its quarterly earnings data on Sunday, November, 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($54.37) by $54.13.
What ETFs hold CureVac's stock?: ETFs with the largest weight of CureVac (NASDAQ:CVAC) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Direxion Moonshot Innovators ETF (MOON), Virtus LifeSci Biotech Clinical Trials ETF (BBC), WisdomTree BioRevolution Fund (WDNA), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB).
What other stocks do shareholders of CureVac own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO).

When did CureVac IPO?: (CVAC) raised $200 million in an IPO on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers.
What is CureVac's stock symbol?: CureVac trades on the NASDAQ under the ticker symbol "CVAC."
Who are CureVac's major shareholders?: CureVac's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (1.70%), BlackRock Inc. (0.88%), Balyasny Asset Management L.P. (0.50%), Alyeska Investment Group L.P. (0.47%), State Street Corp (0.12%) and Credit Suisse AG (0.11%).
How do I buy shares of CureVac?: Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CureVac's stock price today?: One share of CVAC stock can currently be purchased for approximately $9.36.
How much money does CureVac make?: CureVac (NASDAQ:CVAC) has a market capitalization of $2.10 billion and generates $72.33 million in revenue each year.
How many employees does CureVac have?: The company employs 1,049 workers across the globe.
How can I contact CureVac?: CureVac's mailing address is PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG 2M, 72076. The official website for the company is www.curevac.com. The company can be reached via phone at 49-70-71988-30, via email at investors@curevac.com, or via fax at 49-7071-9883.

This page (NASDAQ:CVAC) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial